Centbutindole vs trifluoperazine: a double-blind controlled clinical study in acute schizophrenia
- PMID: 2685263
Centbutindole vs trifluoperazine: a double-blind controlled clinical study in acute schizophrenia
Abstract
Twenty-nine acute schizophrenic patients were treated under double-blind conditions for six weeks with either centbutindole in a dose range of 3 mg/day to 4.5 mg/day or trifluoperazine in the dose range of 15 mg/day to 22.5 mg/day. Both drugs produced a significant improvement in initial psychopathology. No significant differences were demonstrated between the two treatment conditions.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
